Inventiva in the Red: Shares Drop 10%, Support Broken
Inventiva experienced a significant decline on Tuesday, March 31, 2026, dropping 10.21% to €4.31 during the session, following the publication of its annual results for 2025 the previous day. The movement follows a downward trend that has intensified over the past several weeks, with a 17.37% decrease over seven days and a 21.13% decrease over a month. The French biotech is facing multiple negative signals simultaneously at a time when its financing visibility raises questions.
Annual 2025 Results and Stock Weakness
INVENTIVA published its annual results for 2025 on Monday, a milestone that coincides with this new weakness in the stock. The previous session had already ended with a decline, bringing the price down to €4.80, a level that has now been broken downwards this Tuesday morning. The publication highlights a concerning cash situation: according to our information, the company has €230 million in cash, but its financial autonomy does not exceed one year. For a biotech in the clinical development phase, this parameter is nevertheless closely monitored by investors. The finding fuels the selling pressure observed since the beginning of the month, in a market context already strained, with the VIX in an extreme stress zone at 31.05.
Technical Analysis and Market Comparison
From a chart perspective, the most notable signal of the session is the downward breach of the €4.80 support. This level had previously contained declines, and its abandonment opens a bearish path to lower price zones. The 50-day moving average, established at €5.34, is significantly distancing from the current price, confirming the deterioration of the medium-term trend. The RSI, at 36, is approaching the oversold threshold without yet reaching it. The technical configuration remains under pressure, with no established technical rebound signal at this stage. By comparison, benchmark pharmaceutical stocks are moving in the opposite direction this Tuesday: Sanofi is up 1.67% and UCB by 1.26%, highlighting the specific nature of the movement affecting Inventiva, independent of any sector dynamics. Over twelve months, the stock still shows a positive performance of 57.17%, which puts the recent losses into perspective in a longer-term view.
